ACHC | Ticker Profile - Titan Protect

ACHC

Acadia Healthcare Company, Inc.

Healthcare · Medical Care Facilities · NMS

$24.48

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

13.89

Based on estimated future earnings — lower means cheaper

Rev Growth

+7.6%

Year-over-year revenue change

Profit Margin

-32.8%

How much profit the company keeps from each dollar of revenue

ROE

-41.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+23% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 14 analysts covering this stock

About Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilities and eating disorder facilities; comprehensive treatment centers; and residential treatment centers, as well as facilities providing outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

https://www.acadiahealthcare.com

Country: United States Employees: 25,000 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.526

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0580

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.464

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-39.8%

Historical annualised return based on price data

Max Drawdown

-85.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.73

Less volatile than the market — more defensive

52W High

$30.20

19% below the year high

52W Low

$11.43

114% above the year low

Avg Volume

3,021,452

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

38.1%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-12.20

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

124.18

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.71

Healthy liquidity position

Quick Ratio

1.44

Like current ratio but excludes inventory — stricter test

Gross Margin

41.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

10.1%

Profit from core operations before interest and tax

Free Cash Flow

$-216,916,256

Negative — the business is spending more than it generates

Revenue (TTM)

$3.4B

Total revenue over the last 12 months

Net Income

$-1,107,041,024

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$39.00

Target Median

$30.00

Target Low

$13.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go